Simoctocog Alfa API Manufacturers

compare suppliers & get competitive offers

teaser-1024x654-1
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Simoctocog Alfa is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Simoctocog Alfa or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Simoctocog Alfa API 1219013-68-9?

Description:
Here you will find a list of producers, manufacturers and distributors of Simoctocog Alfa. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Simoctocog Alfa 
Cas Number:
1219013-68-9 
DrugBank number:
DB09108 
Unique Ingredient Identifier:
U50VWW6XH6

About Simoctocog Alfa

Here is a short description about Simoctocog alfa. Simoctocog alfa is a recombinant B-domain deleted (BDD) rFVIII produced in genetically modified human embryonic kidney (HEK) 293F cells. The harvested product is concentrated and purified by a series of chromatography steps. It is an antihemorrhagic agent used as a replacement therapy in individuals with Haemophilia A who lack the factor VIII in the intrinsic pathway of blood coagulation system.

As patients with haemophilia A are predisposed to episodes of recurrent bleeding simoctocog alfa can be administered for the treatment or prevention of bleeding such as prior to surgical procedures. Simoctocog alfa is a glycoprotein consisting of 1440 amino acids with an approximate molecular mass of 170 kDa, comprising the FVIII domains A1-A2 + A3-C1-C2 whereas the B-domain, present in the full-length plasma-derived FVIII, has been deleted and replaced by a 16 amino acid linker. Simoctocog alfa is a fourth-generation BDD FVIII product made in the human embryonic kidney (HEK) cell line. Full human post-translational modifications via elimination of potentially immunogenic glycosylation patterns found in non-human cell lines led to decreased immunogenicity and longer half-life.

You can find more info about this product by clicking on the DB ID above.